Please wait while the formulary information is being retrieved.
Drug overview for L-CARNITINE (levocarnitine tartrate):
Generic name: LEVOCARNITINE TARTRATE
Drug class:
Therapeutic class: Electrolyte Balance-Nutritional Products
Amino acid derivative; naturally occurring substance required in mammalian energy metabolism.
No enhanced Uses information available for this drug.
Generic name: LEVOCARNITINE TARTRATE
Drug class:
Therapeutic class: Electrolyte Balance-Nutritional Products
Amino acid derivative; naturally occurring substance required in mammalian energy metabolism.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for L-CARNITINE (levocarnitine tartrate) have been approved by the FDA:
Indications:
None.
Professional Synonyms:
None.
Indications:
None.
Professional Synonyms:
None.
The following dosing information is available for L-CARNITINE (levocarnitine tartrate):
Decreasing the dosage of oral levocarnitine may diminish or eliminate drug-related patient body odor or GI symptoms if present.
Administer orally (as a solution or tablets), by direct IV injection, or by IV infusion.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for L-CARNITINE (levocarnitine tartrate):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for L-CARNITINE (levocarnitine tartrate):
Drug contraindication overview.
Manufacturer states none known.
Manufacturer states none known.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Seizure disorder |
The following adverse reaction information is available for L-CARNITINE (levocarnitine tartrate):
Adverse reaction overview.
Oral therapy: Transient nausea and vomiting, abdominal cramps, diarrhea, body odor. Parenteral therapy: Transient nausea and vomiting, body odor, gastritis. Patients on chronic hemodialysis may experience injection site reactions, headache, pain, diarrhea, flu syndrome, pharyngitis, infection, hypertension, vomiting, abdominal pain, hypotension, dizziness, increased cough, chest pain, hypercalcemia, accidental injury, asthenia, nausea, fever, anemia, hypervolemia, paresthesia, rhinitis, or dyspnea.
Seizures reported in patients, with or without preexisting seizure activity, receiving either oral or IV levocarnitine. Increased seizure frequency and/or severity also reported in patients with preexisting seizure activity.
Oral therapy: Transient nausea and vomiting, abdominal cramps, diarrhea, body odor. Parenteral therapy: Transient nausea and vomiting, body odor, gastritis. Patients on chronic hemodialysis may experience injection site reactions, headache, pain, diarrhea, flu syndrome, pharyngitis, infection, hypertension, vomiting, abdominal pain, hypotension, dizziness, increased cough, chest pain, hypercalcemia, accidental injury, asthenia, nausea, fever, anemia, hypervolemia, paresthesia, rhinitis, or dyspnea.
Seizures reported in patients, with or without preexisting seizure activity, receiving either oral or IV levocarnitine. Increased seizure frequency and/or severity also reported in patients with preexisting seizure activity.
There are 5 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Anaphylaxis Bronchospastic pulmonary disease Laryngeal edema Muscle weakness Seizure disorder |
There are 9 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Abdominal pain with cramps Diarrhea Nausea Vomiting |
Body odor Gastritis |
| Rare/Very Rare |
|---|
|
Facial edema Skin rash Urticaria |
The following precautions are available for L-CARNITINE (levocarnitine tartrate):
Dosage of levocarnitine in pediatric patients <=18 years of age was based on specific patient case record observations rather than on studies that specifically defined age by protocol.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category B.
Distributed into milk in cows; not known whether levocarnitine distributes into human milk. Consider discontinuance of nursing or the drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for L-CARNITINE (levocarnitine tartrate):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for L-CARNITINE (levocarnitine tartrate)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool